-+ 0.00%
-+ 0.00%
-+ 0.00%

*Compass Therapeutics Expects FDA Feedback This Qtr on COMPANION-002 Phase 2/3 Data for Tovecimig (DLL4 X VEGF-A Bispecific Antibody) in Patients With Biliary Tract Cancer >CMPX

Dow Jones·08/06/2026 11:37:00

Please log in to view news